Future research should prioritize preclinical models to test the safety and efficacy of combining IL-4 pathway inhibition with BV, with a particular focus on tumor microenvironment remodeling, CD30 expression kinetics, and cytotoxic immune function. The gene discussed is IL4; the disease is neoplasm.